CRISPR Therapeutics AG [CRSP] stock prices are up 0.31% to $65.33 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CRSP shares have gain 15.79% over the last week, with a monthly amount glided 47.04%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CRISPR Therapeutics AG [NASDAQ: CRSP] stock has seen the most recent analyst activity on February 14, 2025, when Evercore ISI upgraded its rating to a Outperform and also boosted its price target to $99 from $60. Previously, TD Cowen upgraded its rating to Hold on February 12, 2025, and kept the price target unchanged to $35. On February 03, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $65 on the stock. Needham reiterated its Buy rating and decreased its price target to $84 on August 06, 2024. Rodman & Renshaw initiated its recommendation with a Buy and recommended $90 as its price target on August 02, 2024. In a note dated February 15, 2024, Wolfe Research initiated an Peer Perform rating.
The stock price of CRISPR Therapeutics AG [CRSP] has been fluctuating between $30.04 and $66.49 over the past year. Currently, Wall Street analysts expect the stock to reach $65 within the next 12 months. CRISPR Therapeutics AG [NASDAQ: CRSP] shares were valued at $65.33 at the most recent close of the market. An investor can expect a potential drop of -0.51% based on the average CRSP price forecast.
Analyzing the CRSP fundamentals
The CRISPR Therapeutics AG [NASDAQ:CRSP] reported sales of 37.67M for trailing twelve months, representing a surge of 71.63%. Gross Profit Margin for this corporation currently stands at -2.4% with Operating Profit Margin at -12.83%, Pretax Profit Margin comes in at -10.32%, and Net Profit Margin reading is -10.43%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.2 and Total Capital is -0.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that CRISPR Therapeutics AG [NASDAQ:CRSP]’s Current Ratio is 15.64. In addition, the Quick Ratio stands at 15.64 and the Cash Ratio stands at 1.97. Considering the valuation of this stock, the price to sales ratio is 149.78, the price to book ratio is 3.08.
Transactions by insiders
Recent insider trading involved George Simeon, Director, that happened on Jul 16 ’25 when 0.99 million shares were purchased. Chief Medical Officer, Patel Naimish completed a deal on May 29 ’25 to sell 3932.0 shares. Meanwhile, Chief Executive Officer Kulkarni Samarth sold 10031.0 shares on Mar 21 ’25.
